Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients

American Journal of the Medical Sciences

Volumn 348, Issue 6, 2014, Pages 448-454

  Xue, Ling ^a,b   Zhang, Wen Wen ^a,b   Ding, Xiao Liang ^a,b   Zhang, Jing Jing ^a,b   Bao, Jian An ^a   Miao, Li Yan ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Cyclosporine; Hematopoietic stem cell transplant; Personalized therapy; Population pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CREATININE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUCONAZOLE; GENOMIC DNA; GLUCOSE; HEMOGLOBIN; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; NITROGEN; TRIACYLGLYCEROL; UREA; URIC ACID; VORICONAZOLE; ABCB1 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ERYTHROCYTE COUNT; FEMALE; GENETIC POLYMORPHISM; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; THROMBOCYTE COUNT; ALLOTRANSPLANTATION; ANEMIA, APLASTIC; BIOLOGICAL MODEL; COHORT ANALYSIS; GENETICS; GRAFT REJECTION; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES;

ADULT; ANEMIA, APLASTIC; COHORT STUDIES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GRAFT REJECTION; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, HOMOLOGOUS;

EID: 84922394668     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000337     Document Type: Article

References (28)

1. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol 2010;125:S324-35.
2. Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy 2010;2:399-418.
3. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009;373:1550-61.
4. Reddy P, Arora M, Guimond M, et al. GVHD: A continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transpl 2009;15:162-8.
5. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006;45:905-22.
6. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 2006;28:720-5.
7. Marquet P. Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. Ther Drug Monit 2005; 27:727-32.
8. Jacobson PA, Ng J, Green KG, et al. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2003;9:304-11.
9. Zhou H, Gao Y, Cheng XL, et al. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. Eur J Drug Metab Pharmacokinet 2012;37:271-8.
10. Wilhelm AJ, de Graaf P, Veldkamp AI, et al. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Br J Clin Pharmacol 2012;73:553-63.
11. Eljebari H, Gaies E, Fradj NB, et al. Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient. Eur J Clin Pharmacol 2012;68:1517-24.
12. Zhou Y, Sheng XY, Xu JY, et al. Population pharmacokinetic study if cyclosporine in the hematopoietic stem cell transplant recipient. Int J Clin Pharmacol Ther 2013;51:568-75.
13. Hu YF, He J, Chen GL, et al. CYP3A5∗3 and CYP3A4∗18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005;353:187-92.
14. Miao LY, Huang CR, Hou JQ, et al. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008;29:1-5.
15. Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007;46:221-34.
16. Chen B, Zhang W, Gu Z, et al. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol 2011;67:601-12.
17. Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005;33:1268-75.
18. Sun B, Li XY, Gao JW, et al. Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. Ther Drug Monit 2010;32:715-22.
19. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006;1:323-39.
20. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 2003;42:969-84.
21. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol Dial Transpl 1999;14: 1698-703.
22. Romero AJ, Le Pogamp P, Nilsson LG, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
23. Mori T, Aisa Y, Kato J, et al. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: An association with bioavailability of oral solution itraconazole. Int J Hematol 2009;90: 103-7.
24. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002;41:615-37.
25. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49:141-75.
26. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4∗18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007;37:315-27.
27. Qiu XY, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A4∗18B, and CYP3A5∗3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008;64:1069-84.
28. Salm P, Taylor PJ, Rooney F. A high-performance liquid chromatographymass spectrometry method using a novel atmospheric pressurechemical ionization approach for the rapid simultaneous measurement of tacrolimus and cyclosporin in whole blood. Ther Drug Monit 2008; 30:292-300.